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Abstract: Zinc, magnesium, aluminum and copper complexes of several potent, clinically used carbonic
anhydrase (CA) sulfonamide inhibitors, such as acetazolamide, methazolamide, ethoxzolamide and
benzolamide were tested for their possible applications as antacids, in experimental animals. Gastric acid
secretion parameters 3 days after treatment with these CA inhibitors (2 x 500 mg, twice a day), in dogs with
chronic gastric fistulas, led to the observation that the gastric acid parameters BAO (the basal acid output),
and MAO (the maximal acid output after stimulation with histamine) were drastically reduced, as compared
to the same parameters in animals that did not receive these enzyme inhibitors. These are promising results
for the possible use of metal complexes of heterocyclic sulfonamides as treatment alternatives (alone or in
combination with other drugs) for gastric acid secretion imbalances.
Introduction
Carbonic anhydrase (CA, EC 4.2.1.1) together with H+/K+-ATP-ase are the key enzymes involved in
gastric acid secretion.
’4 H
+ ions needed for gastric HCI formation are generated either by hydration of CO_, a
reaction catalyzed by at least two CA isozymes present in gastric parietal cells (CA II cytosolic, and CA IV
membrane-bound form, reaction 1), or by ATP hydrolysis- (reaction 2), in the presence of H+/K+-ATP
I-4 ase"
CO2 + H20 H+ HCO3" + (1)
ATP4"+H20 ADP3"+HPO42"+H
+ (2)
It has been proved that high doses of acetazolamide (5-acetamido-l,3,4-thiadiazole-2-sulfonamide
1), a clinically used sulfonamide CA inhibitor, constitute a useful therapy of gastro-duodenal ulcers, c’5
although side effects correlated with CA inhibition in other tissues than the stomach impeded its wide clinical
applications. The major side effects of acetazolamide as antiulcer drug are correlated with the massive doses
needed for efficient inhibition of gastric CA (around 4 g/day),c and they include: mild paresthesias of the
limbs, slight asthenia and somnolence, enhanced diuresis (in the first 3 days of treatment), weight loss.
1
Mention should be made that the frequency and severity of such side effects are highly decreased in
glaucoma patients taking acetazolamide (as systemic intraocular pressure lowering drug), ld’e since the doses
needed for the ophthalmologic effect of the drug are much more reduced (0.5 1.0 g/day) as compared to the
amount needed for anti-ulcer effects (4 g/day). c
N--N
R---N-sSO2NH2
la" R=Ac
lb: R PhSO
0 MeN_.N MeNsSO2NH2
N
EtO ’SO2NH2
Metal complexes of heterocyclic sulfonamides such as acetazolamide l a, methazolamide 2,
ethoxzolamide 3 or benzolamide b (all clinically used CA inhibitors) reported previously by our group,
have been shown to possess very efficient CA inhibitory properties,
v9 and their mechanism of action has
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been explained as being due to both sulfonamidate anions as well as metal ions (formed after dissociation of
0 the complex in dilute solutions) which interact thereafter with different binding sites of the enzyme.
On the other hand, many pharmacological preparations of the antacid type contain in addition to
sodium bicarbonate (as H neutralizing agent) also Zn(II), Mg(II) and/or AI(III) compounds (mainly as
oxides or hydroxides).
t It appeared thus of interest to investigate whether some of the above-mentioned
metal complexes (alone or in combination), containing the sulfonamides 1-3 as well as the these metal ions
(as well as Cu(II), for reasons that will be explained shortly, would possess properties useful for their
development as antacids, since in addition to the acid neutralizing effects due to their reaction with H ions
present in gastric juice, by their strong CA inhibitory properties they might interfere with gastric acid
secretion by two mechanism of actions: (i) neutralization reactions of the type: (RSO2NH),M + n H+--+ n
RSO2NH2 + M
"+ ;and (ii) CA inhibition by sulfonamides and/or sulfonamide complexes, with the reduction
of H
+ ions generated accordingly to reaction (1). This hypothesis has been verified by some in vivo studies
(in dogs with gastric fistula) reported here. The animals received some of the Zn(II), Mg(II), AI(III) and
Cu(II) complexes of sulfonamides 1-3, and their gastric acid secretion parameters were controlled prior and
after the treatment. Parameters such as BAO (basal acid output), and MAO (maximal acid output after
stimulation with histamine) were drastically reduced in the treated animals, as compared to the same
parameters in animals that did not receive these enzyme inhibitors.
Material and Methods
Sutfonamides used for the preparation of coordination compounds (acetazolamide a, and
methazolamide 2) were from Sigma-Aldrich, benzolamide lb was prepared as described in ref. L2, whereas
ethoxzolamide 3 as described in ref.
3 Metal salts and solvents were from Sigma-Aldrich and were used
without further purification. Human isozymes hCA and II, and bCA IV were prepared as described
previously. Le’d The metal complexes used for the pharmacological evaluations were prepared as described in
previous works of this group.
7" Buffers and 4-nitrophenyl acetate were from Sigma. Inhibitors were assayed
spectrophotometrically at 400 nm, by the esterase method,
4 for the inhibition of 4-nitrophenyl acetate
hydrolysis catalyzed by the three CA isozymes. The buffer used in the enzymatic assay (Tris-H2SO4 10 mM,
pH 7.8) was brought to an ionic strength 0.1, by addition of K2SO4. Enzyme concentrations used in the
experiments were 1.7 nM for hCA II, and 24 nM for bCA IV. Stock solutions of inhibitors (1 raM) were
obtained in DMSO, and dilutions up to 0.01 nM were done thereafter with distilled deionized water. Enzyme
and inhibitor solutions were preincubated for 15 rain prior to assay.
Ex vivo CA activity was determined in gastric mucosa homogenates as follows: precisely weighed
amounts of mucosa (1 3 g) were thoruoghly grinded with glass beads for 15 rain, the cells were then
ultrasonicated and completely lysed in 10-15 mL of distilled water, ultracentrifuged at 12000g for 30 min for
elimination of the cell membranes and other insoluble materials, and the CA activity in the obtained
homogenates was assayed with the esterase method, as described above. Calibration/inhibition curves (in the
presence of sulfonamide inhibitors) were also used in some cases for comparing CA activity in treated vs.
untreated animals. 5’16
Gastric acid secretion parameters BAO (basal acid output), and MAO (maximal acid output after
stimulation with histamine) were determined as described by Lambling et al.,
17 in the gastric juice of Beagle
dogs with chronic gastric fistulas, s by titration with 0.2 N NaOH to pH 7.
s-20 Two animals were used for
each compound studied for its antisecretory properties. The above-mentioned secretion parameters were
measured before the initiation of the treatment, one, two and three days after the treatment, which consisted
in 2 x 500 mg of inhibitor, twice a day, together with the food (12 hours intervals between the administration
of the two doses). CA activity in canine gastric mucosa after 3 days of treatment with some of these CA
inhibitors was determined in some animals which were sacrificed at the end of the experiment, by the
procedure outlined above.
Results and Discussion
The metal complexes 4-15 included in this study were prepared as previously reported,
7 from the
sulfonamide sodium salt and metal salts. Their CA inhibitory properties are shown in Table I.
Modifications of gastric acid secretion parameters in dogs with chronic gastric fistulas after 3 days
treatment with 2 x 500 mg (twice a day) of sulfonamides 1-3 or their metal complexes 4-15 are shown in
Table II.
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CA activity isolated from gastric mucosa of dogs sacrificed after the experiments has also been
assayed (Table III).
Data of Table show that in vitro, sulfonamides 1-3 as well as their metal complexes 4-15 act as
very potent inhibitors of isozymes CA II and CA IV. lsozyme II (the most abundant in gastric mucosa)2’5 is
Table I: Metal complexes of heterocyclic sulfonamide 1-3, of type 4-15 and their CA inhibitory properties
against the isozymes involved in gastric acid secretion, hCA II and bCA IV. Abbreviations: aaz
sulfonamide deprotonated species of acetazolamide; mza sulfonamide deprotonated species of
methazolamide; eza sulfonamide deprotonated species of ethoxzolamide; bza secondary sulfonamide
deprotonated species of benzolamide.
Compound No KI (riM)*
hCA II bCA IV
Haaz (acetazolamide) a 12 220
Hmza (methazolamide) 2 14 240
Heza (ethoxzolamide) 3 4 15
Hbza (benzolamide) b 5 13
Zn(aaz)2 4 6 125
Zn(mza)2 5 8 110
Zn(eza)2 6 4
Mg(aaz)2 7 8 140
Mg(mza)2 8 4 120
Mg(eza)2 9 2 6
Al(aaz)3 10 3 90
Al(mza)3 11 5 95
Al(eza)3 12 3
Al(bza)3(H20)3 13 3 8
Cu(aaz)2 14 3
Cu(eza)2(H20)2 15 0.9 1.7
(h human; b bovine isozyme); *Esterase method,
t4 with.4-NPA as substrate, Tris buffer pH 7.8, 25 C.
more sensitive to this class of inhibitors as compared to isozyme IV, as already shown in previous
communications of our laboratory.
7 Ethoxzolamide and benzolamide were the most potent simple
inhibitors, followed by acetazolamide and methazolamide. This trend was also maintained for their metal
complexes (in which these sulfonamides act as ligands), with the Cu(II) and AI(III) derivatives slightly more
active than the corresponding Zn(II) and Mg(II) complexes.
In vivo data of Table II show that H
+ ion concentration in gastric juice of dogs with chronic gastric
fistula severely drops after 3 days of treatment with 2 x 500 mg CA inhibitors of type 1-13, or combinations
of some of these inhibitors (for instance the AI(III) and Cu(ll) derivatives, such as for (10 + 14) or (12 + 15)
for example. The decrease is more marked in the case of the metal complexes as compared to the parent
sulfonamide. The latter compounds, such as a, 2 and 3, generally induced a decrease of 27 36 % of the
produced titratable gastric acid (first two columns of Table II, expressed as percentuals). In the case of the
sulfonamide metal complexes, the corresponding decrease was of44- 66 % (the least active was the Mg(lI)
derivative 8, with a reduction of 44 %; the largest majority of these complexes induced gastric acid
reductions of around 60- 66 %, being almost doubly as effective as compared to the parent sulfonamides).
The AI(III) complexes 10, 12 and 13 were more efficient as compared to the Zn(II) and Mg(II) derivatives,
but a combination of aluminum and copper complexes such as (10 + 14) or (12 + 15), (Table II) had an even
increased activity. Basal acid output (BAO) was also reduced in the metal complex treated animals as
compared to the control- or sulfonamide only treated ones (third and fourth columns of Table II, expressed in
percentuals). Thus, sulfonamides la-3 produced a 44 50 % reduction ofBAO, after three days of treatment.
Table II" Gastric acid secretion parameters before and 3 days after treatment with CA inhibitors (2 x 500 rag,
twice a day), in dogs with gastric fistula (n 2 for each inhibitor). BAO represents the basal acid output,
whereas MAO the maximal acid output after stimulation with histamine (i.v. injection, 0.05 mg/kg b.w.).
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Treatment
before
[H-] (mEq/L)*
after
treatment
BAO* (mEq/h) MAO* (mEq/h)
before after before after
treatment treatment
None 43.5+1.5
la 48.6+2.7
2 49.2+3.5
3 47.7+3.1
4 54.1+4.0
6 50.8+3.0
8 46.2+4.5
lO 45.1+3.8
10 + 14" 46.8+3.0
12 44.5+2.0
13 47.1+2.1
12 + 15 45.2+3.7
44.7+2.3 5.2+0.3 5.1+0.1 20.5+0.3 20.0+ 1.9
32.2+ 1.6 5.9__+0.4 3.0_+0.3 22.6_+0.5 15.1 +0.8
35.8_+2.9 6.0_+ 1.1 3.3+0.4 21.7-+0.9 16.0+ 1.2
30.4-+2.0 5.6+0.5 3.1-+0.2 23.4+ 1.3 15.8+2.1
21.5-+ 1.9 5.9-+0.5 2.1-+0.2 26.8-+2.5 7.4_+2.5
17.2_+2.4 5.5_+0.7 1.6_+0.1 25.0_+2.9 6.1_+1.0
25.7_+2.2 6.3+0.9 3.5_+0.5 24.8_+3.1 9.9_+ 1.3
20.0_+ 1.4 5.8_+0.6 1.7+0.3 23.9_+2.6 5.4_+2.1
17.1 +0.8 6.0_+ 1.2 1.1_+0.2 19.4+0.9 4.6+__ 1.1
18.3_+2.6 5.7_+0.9 1.4+-0.4 26.5_+0.4 4.9_+ 1.0
17.9_+1.4 5.9_+1.1 1.3_+0.5 26.0_+0.7 4.7_+1.2
15.2_+0.7 5.1_+0.59 0.9_+0.2 26.8_+ 1.5 4.0+-0.5
*Mean _+ standard deviation (n=3).
The animal was treated with a combination of450 mg AI(III) complex + 50 mg Cu(II) complex.
The corresponding reductions for the animals treated with the metal complexes were of 44 -82 %
(again with the Mg(lI) derivative possessing the lowest activity of 44 %). The majority of the investigated
compounds reduced BAO with 70- 82 % as compared to the same parameter in the control animals. The
histamine-stimulated secretion (MAO) were also markedly decreased in the animals treated with these CA
inhibitors. (fifth and sixth columns of Table II, expressed in percentuals). Thus, sulfonamides 1-3, generally
decreased MAO with 26 33 % after three days of treatment. In contrast, sulfonamide metal complexes
induced a reduction of 60 85 % of this parameter. The AI(III), Zn(II) and (aluminum + copper) complex
combinations were again the best MAO inhibitors.
Table III: Total CA activity (CA II + CA IV) from canine gastric mucosa after 3 days of treatment with CA
inhibitors oftype 1-15.
Inhibitor CA activity (EU/mg)*
None 1.28 + 0.05
la 0.54 -+ 0.04
3 0.46 -+ 0.06
4 0.28 -+ 0.07
6 0.20 +- 0.05
(10 + 14) 0.11 + 0.09
12 O. 13 + 0.08
(12 + 15) 0.10 _+ 0.06
*Mean + standard deviation (n=3 different samples of the same animal).
The animal was treated with a combination of450 mg AI(III) complex + 50 mg Cu(II) complex.
The inclusion of the copper complexes 14 and 15 in this study (in combination with the
corresponding aluminum complexes, in order to avoid severe toxicity problems induced by this essential but
highly toxic trace element)
2 is due to the following facts. It has been reported22’23 that treatment with zinc
compounds (zinc is involved in a variety of common, chronic or viral diseases) may disturb the copper
homeostasis in the organism, leading to depletion of Cu
2+ ions in many tissues/organs.
2-23 It is thus of
crucial importance to supplement this trace element exogenously, when relatively high amounts of zinc
6OMarc A. Hies et al. Metal-BasedDrugs
derivatives are used in therapy.
23 A copper complex, such as 14 or 15 added to the antacid treatment based on
the zinc and/or aluminum sulfonamide complexes reported here, would alleviate/avoid this problem.
Total CA (CA II + CA IV) activity in gastric mucosa of the animals treated as above proved a strong
inhibition of these enzymes in the case in which the sulfonamides/metal complexes have been administered
for three days (Table III). Thus, 3 days treatment with sulfonamides 1-3 led to a 57-64 % inhibition of the
gastric CAs, whereas the metal complexes (alone of in combination) induced a much stronger inhibition, of
78 92 % (Table III, data expressed in percentuals).
All these data prompt us to propose the Zn(II), Mg(II)and AI(III)sulfonamide complexes
(eventually in combination with trace amounts of the corresponding copper derivatives) as a valuable new
class of antacid derivatives, acting probably by a double mechanism: neutralization of hydrogen ions by a
normal acid-base neutralization reaction, coupled with a strong inhibition of carbonic anhydrase isozymes
present in the gastric mucosa, followed by reduction of formation ofH
+ ions due to COz hydration. It is not to
exclude other mechanisms of action of our compounds, such as interaction with the histamine release
processes from mastocytes or basophils, since it has been proved that Zn(II) salts of inorganic or organic acid
inhibit these processes,
z4 On the other hand, histamine is a powerful CA activator,z5’26 and the X-ray
crystallographic structure of the histamine-hCA II adduct has only recently been reported by this group,
z7 It is
thus possible that the strong gastric acid secretion inhibitory properties observed in vivo for the metal
complexes of heterocyclic sulfonamides, is due to intricate mechanisms correlating their acid neutralizing
capacity with the strong CA inhibitory properties, as well as interaction with the histamine activatory
properties upon CA and HCI secretion within the stomach. Since gastric ulcers are presently treated with a
variety of very efficient therapies (histamine-H2 blockers, H+/K+-ATP-ase inhibitors, etc)c we do not propose
these compounds as a new anti-ulcer therapy, but as an interesting alternative to the classical and widely used
antacids, which generally act as simple acid-base neutralizing compounds. Compounds of the type described
here should be used alone or in combination with other acid neutralizing compounds (sodium bicarbonate;
MgO; ZnO; AIO(OH), etc). A detailed study regarding such combinations is needed.
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